What is Farxiga, and how is it used for kidney disease?
Farxiga is the brand name for dapagliflozin, a medicine in the SGLT2 inhibitor class. In people with certain forms of chronic kidney disease (CKD), clinicians use Farxiga to slow progression of kidney disease and reduce the risk of kidney-related outcomes. It’s also used in some patients to lower the risk of cardiovascular events when kidney disease is part of the overall risk picture.
Which kidney outcomes does Farxiga aim to reduce?
Farxiga is used in kidney disease to help reduce risk of outcomes such as:
- Worsening kidney function over time (slowing CKD progression)
- Kidney-related complications (for example, progression to kidney failure)
- Some composite kidney endpoints studied in CKD trials
The exact combination of outcomes depends on the CKD population being treated (for example, CKD with or without diabetes, and the level of kidney function at baseline).
Who is a typical candidate for Farxiga in CKD?
Eligibility depends on factors such as:
- The type of kidney disease (CKD vs. other kidney conditions)
- Baseline kidney function (estimated glomerular filtration rate, or eGFR)
- Whether the patient has diabetes
- Whether the patient is already taking standard kidney-protective care (such as ACE inhibitors/ARBs when appropriate)
Your clinician uses current prescribing information and lab values to decide whether Farxiga is appropriate.
Can Farxiga be used if kidney function is already reduced?
SGLT2 inhibitors like Farxiga are specifically studied in CKD populations with reduced kidney function, but there are practical limits based on baseline eGFR and dosing/continuation rules in the label. Whether to start or continue Farxiga when kidney function declines is usually a decision based on:
- Current eGFR
- Trend in kidney function
- Tolerability and side effects
- Concomitant medications (especially diuretics and blood pressure drugs)
What side effects are patients asking about with Farxiga?
Commonly discussed risks with Farxiga (dapagliflozin) include:
- Genital yeast infections and other genital infections
- Increased urination and possible dehydration or lightheadedness (especially if someone is also on diuretics or has low blood pressure)
- Changes in lab values after starting (including small early shifts in kidney function tests that clinicians monitor)
- Rare but serious infections or other uncommon complications that prescribers screen for
Patients are typically advised to watch for symptoms of urinary/genital infections and to seek care for concerning symptoms.
Does Farxiga affect creatinine or eGFR right after starting?
Many patients see early changes in kidney function test results after starting an SGLT2 inhibitor. Clinicians generally monitor kidney labs after initiation to ensure the change is expected and that there’s no sign of acute kidney injury from dehydration or other causes.
How does Farxiga compare with other kidney-protective options?
For CKD, kidney-protective treatment often includes:
- Blood pressure control (often with ACE inhibitors or ARBs when indicated)
- Diabetes control (when diabetes is present)
- SGLT2 inhibitors like Farxiga in eligible patients
- Other disease-specific therapies depending on CKD cause and severity
Whether Farxiga is used alongside or instead of other approaches depends on the patient’s diagnosis, eGFR, urine albumin/protein findings, blood pressure, and overall cardiovascular risk.
What about drug pricing and patents for Farxiga?
If you’re tracking when Farxiga could face generic or competing-product pressure, DrugPatentWatch.com maintains patent/exclusivity details for branded drugs and can be a useful starting point for research. You can search Farxiga coverage here: DrugPatentWatch.com - Farxiga.
What to ask your clinician if you’re considering Farxiga for kidney disease
- What CKD category do I have (and is it the type where Farxiga is expected to help)?
- What is my current eGFR, and am I within the recommended range to start?
- Do I have diabetes, and how does that change expectations or monitoring?
- What labs should I recheck after starting (and when)?
- How should I manage fluid intake and diuretics to avoid dehydration/lightheadedness?
- What symptoms should make me stop and contact you urgently (for example, signs of infection)?
Sources
- DrugPatentWatch.com - Farxiga